What is the 13F Pro Quality Score for BHVN?

13F Pro ranks Biohaven Ltd. (BHVN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BHVN's current score at https://13fpro.ai/research/BHVN (free sign-up required for the full ranking).

Where does 13F Pro source BHVN data?

All Biohaven Ltd. fundamentals and ownership data come directly from SEC EDGAR. Biohaven Ltd. files with the SEC under CIK 1935979. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BHVN in?

Biohaven Ltd. (BHVN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BHVN research updated on 13F Pro?

BHVN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Biohaven Ltd.(BHVN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1935979 BHVN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

BHVN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Biohaven Ltd. (BHVN), a Healthcare sector company. BHVN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Biohaven Ltd. reports net income of $-130.5M, free cash flow of $-149.9M. Top institutional holders of BHVN by reported 13-F value include JANUS HENDERSON GROUP PLC, BlackRock,, SUVRETTA CAPITAL MANAGEMENT,, based on the most recent SEC filings. BHVN trades on the NYSE exchange and files with the SEC under CIK 1935979. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BHVN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Biohaven Ltd. directly from SEC EDGAR.

Net Income

Q1 2026

$-130.5M

Free Cash Flow

Q1 2026

$-149.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+12.7% YoY

$-738.8MFY 2025

FY22 $-570.3MFY23 $-408.2MFY24 $-846.4MFY25 $-738.8M

Operating Income

+15.8% YoY

$-745.4MFY 2025

FY22 $-567.9MFY23 $-436.1MFY24 $-885.1MFY25 $-745.4M

EPS (Diluted)

+26.1% YoY

$-6.86FY 2025

FY22 $-12.75FY23 $-5.73FY24 $-9.28FY25 $-6.86

Total Assets

-26.6% YoY

$451.4MFY 2025

FY22 $661.8MFY23 $513.2MFY24 $615.1MFY25 $451.4M

Op. Cash Flow

-4.6% YoY

$-609.4MFY 2025

FY22 $-297.7MFY23 $-331.7MFY24 $-582.5MFY25 $-609.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Net Income	$-738.8M +12.7%	$-846.4M -107.4%	$-408.2M +28.4%	$-570.3M -380.6%	$-118.7M	—
Operating Income	$-745.4M +15.8%	$-885.1M -103.0%	$-436.1M +23.2%	$-567.9M -396.0%	$-114.5M	—
EPS (Diluted)	$-6.86 +26.1%	$-9.28 -62.0%	$-5.73 +55.1%	$-12.75 -323.6%	$-3.01	—
Total Assets	$451.4M -26.6%	$615.1M +19.9%	$513.2M -22.5%	$661.8M	—	—
Operating Cash Flow	$-609.4M -4.6%	$-582.5M -75.6%	$-331.7M -11.4%	$-297.7M -291.9%	$-76.0M	—

AI Insight: BHVN Financial Trends

BHVN burned through $600M+ in shareholder equity over 7 quarters, now showing sequential improvement in operating losses despite negative equity in Q3 2025.

• Operating losses steadily improved from $-334M in Q2 2024 to $-130M in Q1 2026.

• Net losses decreased from $-222M in Q1 2025 to $-131M in Q1 2026.

• Equity fell from $384M in Q2 2024 to $130M in Q1 2026.

⚠ Company went negative equity in Q3 2025 at $-17M before recovering to $130M in Q1 2026.

⚠ Operating cash flow remains consistently negative around $-150M per quarter with no clear improvement trend.

AI Insight: BHVN Ratio Trends

Data is too sparse to identify meaningful trends, with only one ROE data point showing -176.5% in Q4 2024.

• ROE was deeply negative at -176.5% in Q4 2024, the only available profitability metric.

⚠ Complete absence of operating margin, net margin, and return metrics across most quarters limits visibility.

Get alerted when BHVN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Biohaven Ltd. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BHVN

JANUS HENDERSON GROUP PLC
$148.2M17,534,612 sh
BlackRock, Inc.
$94.9M11,222,407 sh
SUVRETTA CAPITAL MANAGEMENT, LLC
$87.0M10,286,937 sh
STIFEL FINANCIAL CORP
$84.1M9,940,885 sh
STATE STREET CORP
$56.0M6,618,803 sh
INFINITUM ASSET MANAGEMENT, LLC
$52.9M6,250,000 sh
TCG Crossover Management, LLC
$39.2M4,631,317 sh
Royalty Pharma Sub-Manager, LLC
$24.8M2,936,507 sh
D. E. Shaw & Co., Inc.
$24.1M2,847,193 sh
GEODE CAPITAL MANAGEMENT, LLC
$23.4M2,767,763 sh

Fund	Value	Shares
JANUS HENDERSON GROUP PLC	$148.2M	17,534,612
BlackRock, Inc.	$94.9M	11,222,407
SUVRETTA CAPITAL MANAGEMENT, LLC	$87.0M	10,286,937
STIFEL FINANCIAL CORP	$84.1M	9,940,885
STATE STREET CORP	$56.0M	6,618,803
INFINITUM ASSET MANAGEMENT, LLC	$52.9M	6,250,000
TCG Crossover Management, LLC	$39.2M	4,631,317
Royalty Pharma Sub-Manager, LLC	$24.8M	2,936,507
D. E. Shaw & Co., Inc.	$24.1M	2,847,193
GEODE CAPITAL MANAGEMENT, LLC	$23.4M	2,767,763

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BHVN on your watchlist

Track score changes the day Biohaven Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BHVN a good stock to buy?

13F Pro's AI-powered analysis of Biohaven Ltd. (BHVN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BHVN are available on the BHVN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BHVN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BHVN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Biohaven Ltd.'s investment landscape.